Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

p73 regulates epidermal wound healing and induced keratinocyte programming.

Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA.

PLoS One. 2019 Jun 19;14(6):e0218458. doi: 10.1371/journal.pone.0218458. eCollection 2019.

2.

Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Jun 11. pii: molcanres.0257.2019. doi: 10.1158/1541-7786.MCR-19-0257. [Epub ahead of print]

PMID:
31186280
3.

More Information Needed on Probiotic Supplement Product Labels.

Merenstein D, Guzzi J, Sanders ME.

J Gen Intern Med. 2019 Jun 3. doi: 10.1007/s11606-019-05077-5. [Epub ahead of print] No abstract available.

PMID:
31161565
4.

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda NFDCC, Trajanoski Z.

Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6.

5.

Improving End-User Trust in the Quality of Commercial Probiotic Products.

Jackson SA, Schoeni JL, Vegge C, Pane M, Stahl B, Bradley M, Goldman VS, Burguière P, Atwater JB, Sanders ME.

Front Microbiol. 2019 Apr 17;10:739. doi: 10.3389/fmicb.2019.00739. eCollection 2019. Review.

6.

Author Correction: Drug response in organoids generated from frozen primary tumor tissues.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC.

Sci Rep. 2019 Apr 24;9(1):6517. doi: 10.1038/s41598-019-42133-w.

7.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.

Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.

8.

Effects of land vs water jump exercise: Implications for exercise design targeting bone health.

Chien KY, Chang WG, Sanders ME, Chen CH, Wu WC, Chen WC.

Scand J Med Sci Sports. 2019 Jun;29(6):826-834. doi: 10.1111/sms.13410. Epub 2019 Mar 29.

PMID:
30779462
9.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
10.

Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):874. doi: 10.1158/0008-5472.CAN-18-4086. No abstract available.

PMID:
30770369
11.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
12.

Enhancing Parathyroid Gland Visualization Using a Near Infrared Fluorescence-Based Overlay Imaging System.

McWade MA, Thomas G, Nguyen JQ, Sanders ME, Solórzano CC, Mahadevan-Jansen A.

J Am Coll Surg. 2019 May;228(5):730-743. doi: 10.1016/j.jamcollsurg.2019.01.017. Epub 2019 Feb 13.

PMID:
30769112
13.

Probiotic Safety-Reasonable Certainty of No Harm.

Cabana MD, Salminen S, Sanders ME.

JAMA Intern Med. 2019 Feb 1;179(2):276. doi: 10.1001/jamainternmed.2018.7498. No abstract available.

PMID:
30715110
14.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

15.

Innovative surgical guidance for label-free real-time parathyroid identification.

Thomas G, McWade MA, Nguyen JQ, Sanders ME, Broome JT, Baregamian N, Solórzano CC, Mahadevan-Jansen A.

Surgery. 2019 Jan;165(1):114-123. doi: 10.1016/j.surg.2018.04.079. Epub 2018 Nov 12.

PMID:
30442424
16.

'Brain Fogginess' and D-Lactic Acidosis: Probiotics Are Not the Cause.

Quigley EMM, Pot B, Sanders ME.

Clin Transl Gastroenterol. 2018 Sep 24;9(9):187. doi: 10.1038/s41424-018-0057-9. No abstract available.

17.

Does probiotic consumption reduce antibiotic utilization for common acute infections? A systematic review and meta-analysis.

King S, Tancredi D, Lenoir-Wijnkoop I, Gould K, Vann H, Connors G, Sanders ME, Linder JA, Shane AL, Merenstein D.

Eur J Public Health. 2019 Jun 1;29(3):494-499. doi: 10.1093/eurpub/cky185.

18.

Developing a Clinical Prototype to Guide Surgeons for Intraoperative Label-Free Identification of Parathyroid Glands in Real Time.

Thomas G, McWade MA, Paras C, Mannoh EA, Sanders ME, White LM, Broome JT, Phay JE, Baregamian N, Solórzano CC, Mahadevan-Jansen A.

Thyroid. 2018 Nov;28(11):1517-1531. doi: 10.1089/thy.2017.0716. Epub 2018 Sep 11.

PMID:
30084742
19.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM.

Oncoimmunology. 2018 Mar 6;7(6):e1438106. doi: 10.1080/2162402X.2018.1438106. eCollection 2018.

20.

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.

Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM.

Nat Commun. 2018 Jan 16;9(1):248. doi: 10.1038/s41467-017-02630-w.

21.

Shared mechanisms among probiotic taxa: implications for general probiotic claims.

Sanders ME, Benson A, Lebeer S, Merenstein DJ, Klaenhammer TR.

Curr Opin Biotechnol. 2018 Feb;49:207-216. doi: 10.1016/j.copbio.2017.09.007. Epub 2017 Nov 10. Review.

22.

Post-irradiation morphoea of the breast: a case report and review of the literature.

Gonzalez-Ericsson PI, Estrada MV, Al-Rohil R, Sanders ME.

Histopathology. 2018 Jan;72(2):342-350. doi: 10.1111/his.13343. Epub 2017 Nov 7. Review.

PMID:
29110314
23.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

24.

Paper incompletely describes evidence-based usage of probiotics.

Sanders ME, Younes J.

Gut Microbes. 2018 Mar 4;9(2):102-103. doi: 10.1080/19490976.2017.1393143. Epub 2017 Nov 8. No abstract available.

25.

Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment.

Thomas G, Nguyen TQ, Pence IJ, Caldwell B, O'Connor ME, Giltnane J, Sanders ME, Grau A, Meszoely I, Hooks M, Kelley MC, Mahadevan-Jansen A.

Sci Rep. 2017 Oct 19;7(1):13548. doi: 10.1038/s41598-017-13237-y.

26.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL.

Cell Metab. 2017 Oct 3;26(4):633-647.e7. doi: 10.1016/j.cmet.2017.09.009.

27.

Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.

Ooft ML, van Ipenburg JA, Sanders ME, Kranendonk M, Hofland I, de Bree R, Koljenović S, Willems SM.

J Clin Pathol. 2018 Mar;71(3):267-274. doi: 10.1136/jclinpath-2017-204664. Epub 2017 Sep 6.

PMID:
28877959
28.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

29.

Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.

Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G.

Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. doi: 10.1038/nrgastro.2017.75. Epub 2017 Jun 14. Review.

30.

Reliability and Accuracy of a Standardized Shallow Water Running Test to Determine Cardiorespiratory Fitness.

Nagle EF, Sanders ME, Gibbs BB, Franklin BA, Nagle JA, Prins PJ, Johnson CD, Robertson RJ.

J Strength Cond Res. 2017 Jun;31(6):1669-1677. doi: 10.1519/JSC.0000000000001638.

PMID:
28538319
31.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

32.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

33.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1. Erratum in: Cancer Res. 2019 Feb 15;79(4):874.

34.

Safety of Bifidobacterium animalis Subsp. Lactis (B. lactis) Strain BB-12-Supplemented Yogurt in Healthy Children.

Tan TP, Ba Z, Sanders ME, D'Amico FJ, Roberts RF, Smith KH, Merenstein DJ.

J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):302-309. doi: 10.1097/MPG.0000000000001272.

35.

Probiotic use in at-risk populations.

Sanders ME, Merenstein DJ, Ouwehand AC, Reid G, Salminen S, Cabana MD, Paraskevakos G, Leyer G.

J Am Pharm Assoc (2003). 2016 Nov - Dec;56(6):680-686. doi: 10.1016/j.japh.2016.07.001.

36.

A Phyllodes-like Mammary Tumor in a Breeding Galago (Otolemur garnettii).

Jones CP, Apple TM, Burton BJ, Sanders ME, Boyd KL, Salleng KJ.

Comp Med. 2016;66(5):424-428.

37.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.

Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17. Review.

38.

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW.

Cancer. 2016 Oct;122(19):2971-8. doi: 10.1002/cncr.30153. Epub 2016 Jun 28.

39.

Aquatic High Intensity Interval Training for Cardiometabolic Health: Benefits and Training Design.

Nagle EF, Sanders ME, Franklin BA.

Am J Lifestyle Med. 2016 Jun 22;11(1):64-76. doi: 10.1177/1559827615583640. eCollection 2017 Jan-Feb. Review.

40.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

41.

Probiotics and microbiota composition.

Sanders ME.

BMC Med. 2016 Jun 2;14(1):82. doi: 10.1186/s12916-016-0629-z.

42.

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL.

Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28.

43.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):.

44.

Advancing probiotic research in humans in the United States: Challenges and strategies.

Sanders ME, Shane AL, Merenstein DJ.

Gut Microbes. 2016;7(2):97-100. doi: 10.1080/19490976.2016.1138198. Epub 2016 Mar 10.

45.

Probiotic nomenclature matters.

Hill C, Scott K, Klaenhammer TR, Quigley E, Sanders ME.

Gut Microbes. 2016;7(1):1-2. doi: 10.1080/19490976.2015.1127484. No abstract available.

46.

Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.

Wang J, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, Chandraratna RA, Sanders ME, Janesick A, Blumberg B, Ward L, Ho L, Pasinetti GM.

Oncotarget. 2016 Feb 16;7(7):7469-79. doi: 10.18632/oncotarget.7191.

47.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM.

Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582.

48.

Drug response in organoids generated from frozen primary tumor tissues.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC.

Sci Rep. 2016 Jan 7;6:18889. doi: 10.1038/srep18889. Erratum in: Sci Rep. 2019 Apr 24;9(1):6517.

49.

Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification.

Lyle PL, Bridge JA, Simpson JF, Cates JM, Sanders ME.

Histopathology. 2016 Jun;68(7):1040-5. doi: 10.1111/his.12898. Epub 2016 Jan 19.

PMID:
26542423
50.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.

Supplemental Content

Loading ...
Support Center